Ledipasvir
Ledipasvir. HCV NS5A inhibitor — disrupts NS5A protein function, blocking viral replication and assembly. Co-formulated with sofosbuvir as… Oral half-life 47 h.
HCV NS5A inhibitor — disrupts NS5A protein function, blocking viral replication and assembly. Co-formulated with sofosbuvir as Harvoni for genotype 1/4/5/6 HCV — 12-week course with > 95% cure rate.
PK: its citation is a NARRATIVE REVIEW by the manufacturer, with no study, no subject count and no dose. The half-life of 47 h is verbatim there and is retained on that footing, but it CONFLICTS WITH THE PRIMARY, which reports "an extended plasma half-life of 37-45 h in healthy volunteers" — 47 lies outside that range. Every value derives from the fixed-dose combination because ledipasvir is never given alone. V 290 L appears in no abstract and is byte-identical to RALTEGRAVIR stored volume, from a paper that likewise states none — a duplicated placeholder across two unrelated antivirals. No intravenous formulation exists, so F is pinned to 1. ka 0.32 dropped; absorption is modelled zero-order with a lag.
Pharmacokinetics
- Oral — t½ 47 h · F 100%
Sources: PMID:27193156, PMID:24320933